Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Biweekly Administration of Docetaxel and Gemcitabine as Adjuvant Therapy for Stage II and IIIA Non-small Cell Lung Cancer: A Phase II Study

KONSTANTINOS N. SYRIGOS, MARIOS KONSTANTINOU, EVANGELLOS SEPSAS, GEORGE PAPAMICHALES, ACHILLEAS LOULLIAS, IONAS BELENIS, IONAS SKOTTIS, ANDRIANI CHARPIDOU and CHARALAMBOS ROUSSOS
Anticancer Research July 2007, 27 (4C) 2887-2892;
KONSTANTINOS N. SYRIGOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: knsyrigos@usa.net ksyrigos@med.uoa.gr
MARIOS KONSTANTINOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EVANGELLOS SEPSAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGE PAPAMICHALES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ACHILLEAS LOULLIAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IONAS BELENIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IONAS SKOTTIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDRIANI CHARPIDOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHARALAMBOS ROUSSOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The aim of this study was to determine the overall survival, progression-free survival, and toxicity associated with adjuvant administration of docetaxel and gemcitabine for completely resected patients with stage II and IIIA non-small cell lung cancer (NSCLC). Patients and Methods: Thirty-nine eligible patients had surgical resection for pathological stage II or IIIA disease and received postoperative gemcitabine 1000 mg/m2 followed by docetaxel 80 mg/m2 on days 1 and 14. Cycles were repeated every 28 days. Results: Treatment compliance was acceptable, at 83%. The median duration of follow-up, time to disease progression, and overall survival was 36.7 months, 17 months and 21 months, respectively. Toxicities were acceptable. Treatment failure revealed brain metastasis (15%), intrathoracic recurrence (24%) and systemic metastasis (36%). Conclusion: The biweekly administration of docetaxel and gemcitabine is a safe, well-tolerated and convenient chemotherapy regimen in the adjuvant setting of completely resected NSCLC stage II and III, with efficacy similar to that reported in other regimens. Hence, this non-platinum based regimen appears promising and warrants further evaluation.

  • Adjuvant chemotherapy
  • combined modality treatment
  • non-platinum regimen
  • non-small cell lung carcinoma
  • Received March 15, 2007.
  • Revision received May 31, 2007.
  • Accepted June 4, 2007.
  • Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 27 (4C)
Anticancer Research
Vol. 27, Issue 4C
July-August 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Biweekly Administration of Docetaxel and Gemcitabine as Adjuvant Therapy for Stage II and IIIA Non-small Cell Lung Cancer: A Phase II Study
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Biweekly Administration of Docetaxel and Gemcitabine as Adjuvant Therapy for Stage II and IIIA Non-small Cell Lung Cancer: A Phase II Study
KONSTANTINOS N. SYRIGOS, MARIOS KONSTANTINOU, EVANGELLOS SEPSAS, GEORGE PAPAMICHALES, ACHILLEAS LOULLIAS, IONAS BELENIS, IONAS SKOTTIS, ANDRIANI CHARPIDOU, CHARALAMBOS ROUSSOS
Anticancer Research Jul 2007, 27 (4C) 2887-2892;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Biweekly Administration of Docetaxel and Gemcitabine as Adjuvant Therapy for Stage II and IIIA Non-small Cell Lung Cancer: A Phase II Study
KONSTANTINOS N. SYRIGOS, MARIOS KONSTANTINOU, EVANGELLOS SEPSAS, GEORGE PAPAMICHALES, ACHILLEAS LOULLIAS, IONAS BELENIS, IONAS SKOTTIS, ANDRIANI CHARPIDOU, CHARALAMBOS ROUSSOS
Anticancer Research Jul 2007, 27 (4C) 2887-2892;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Docetaxel plus Gemcitabine as First-line Treatment in Malignant Pleural Mesothelioma: A Single Institution Phase II Study
  • Therapy-induced Toxicity of the Lungs: An Overview
  • Google Scholar

More in this TOC Section

  • The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
  • Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
  • Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2022 Anticancer Research

Powered by HighWire